再発性低悪性度B細胞非ホジキンリンパ腫（iNHL）におけるコパンリシブとリツキシマブ

基本情報

NCT ID

NCT02367040

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

458

治験依頼者名

Bayer

概要

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free interval of ≥ 12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.

対象疾患

介入

依頼者（Sponsor）